TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12689781

Group type: EXPERIMENTAL
Intervention: Cable-released falls in older adults
Number of subjects: 20

Group type: COMPARATOR
Intervention: Self-initiated falls in older adults
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cable-released falls in young males
Number of subjects: 20

Group type: COMPARATOR
Intervention: Self-initiated falls in young males
Number of subjects: 20
Study: 11119402

Group type: EXPERIMENTAL
Intervention: Hormone therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observational studies
Number of subjects: 0
Study: 9089669

Group type: EXPERIMENTAL
Intervention: Clonidine (1.5 micrograms kg‐1 in 10 ml infused intravenously over 10 min) at 20 degrees C
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Clonidine (1.5 micrograms kg‐1 in 10 ml infused intravenously over 10 min) at 40 degrees C
Number of subjects: 8

Group type: COMPARATOR
Intervention: High ambient temperature (40 degrees C)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (physiological saline infused intravenously over 10 min) at 20 degrees C
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (physiological saline infused intravenously over 10 min) at 40 degrees C
Number of subjects: 8
Study: 1304177

Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer dentifrice (0.3% triclosan and 2% copolymer of methoxyethylene and maleic acid)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo dentifrice (0.243% sodium fluoride in a silica base)
Number of subjects: 159
Study: 4013627

Group type: EXPERIMENTAL
Intervention: Intercostal block (i.c.b.) after subcostal incision
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Second intercostal block (i.c.b.) 8 hours after the first one
Number of subjects: 94

Group type: COMPARATOR
Intervention: Centrally acting analgesics alone
Number of subjects: 94
Study: 31394525

Group type: EXPERIMENTAL
Intervention: Morning vaccination
Number of subjects: 26

Group type: COMPARATOR
Intervention: Evening vaccination
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both groups (morning and evening)
Number of subjects: 26
Study: 30185931

Group type: EXPERIMENTAL
Intervention: Thyroid hormone replacement treatment
Number of subjects: 1034

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1034
Study: 25611082

Group type: EXPERIMENTAL
Intervention: High-intensity intermittent exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moderate-intensity continuous exercise
Number of subjects: 0
Study: 25190728

Group type: EXPERIMENTAL
Intervention: Soy protein supplementation (n = 70)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo (n = 70)
Number of subjects: 140
Study: 22872368

Group type: EXPERIMENTAL
Intervention: End-expiratory levels (EEL) with normal tidal volume
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Increased tidal volume (V (T)) with maintained normal EEL (FRC)
Number of subjects: 10
Study: 20130482

Group type: EXPERIMENTAL
Intervention: Tai chi (TC)
Number of subjects: 35
Study: 19022123

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) administered into extraction sockets
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no PRP treatment)
Number of subjects: 12
Study: 16798622

Group type: EXPERIMENTAL
Intervention: subcutaneous recombinant interleukin-2 (rIL-2) plus antiretroviral therapy (ART)
Number of subjects: 4150

Group type: COMPARATOR
Intervention: ART alone
Number of subjects: 4150
Study: 14714359

Group type: EXPERIMENTAL
Intervention: Jiexiao Oral Liquid (JXOL)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Virazole (10-15 mg.kg-1.d-1)
Number of subjects: 160
Study: 11084104

Group type: EXPERIMENTAL
Intervention: Single biphasic shock from right ventricle + left ventricle‐ ‐> superior vena cava+ + CAN+
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Dual biphasic shock from right ventricle‐ ‐> superior vena cava+ + CAN+ followed by another 40% tilt biphasic shock from left ventricle‐ ‐> superior vena cava+ + CAN+
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard ICD shock configuration (Control: right ventricle‐ ‐> superior vena cava+ + CAN+)
Number of subjects: 51
Study: 9363044

Group type: EXPERIMENTAL
Intervention: Abecarnil (high dosage)
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Abecarnil (low dosage)
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 464

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 464
Study: 1526085

Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide (5 mg daily for 1 week)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Transbuccal nitroglycerin (0.25 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Unmedicated
Number of subjects: 32
Study: 3532744

Group type: EXPERIMENTAL
Intervention: Risk factors (serum cholesterol concentration, diastolic blood pressure, cigarette smoking)
Number of subjects: 325348

Group type: EXPERIMENTAL
Intervention: Elimination of risk factors
Number of subjects: 325348
Study: 30452706

Group type: EXPERIMENTAL
Intervention: 2% rapeseed oil
Number of subjects: 1080

Group type: EXPERIMENTAL
Intervention: 4% rapeseed oil
Number of subjects: 1080

Group type: EXPERIMENTAL
Intervention: Rapeseed oil
Number of subjects: 1080

Group type: EXPERIMENTAL
Intervention: MH rapeseed oil
Number of subjects: 1080

Group type: EXPERIMENTAL
Intervention: Low erucic acid or 2% rapeseed oil
Number of subjects: 1080

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1080
Study: 29776960

Group type: EXPERIMENTAL
Intervention: Folic acid (2.5 mg), vitamin B6 (50 mg), vitamin B12 (1 mg)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 27083381

Group type: EXPERIMENTAL
Intervention: Miller blade
Number of subjects: 30

Group type: COMPARATOR
Intervention: GlideScope
Number of subjects: 30

Group type: COMPARATOR
Intervention: Truview PCD
Number of subjects: 30
Study: 24939906

Group type: EXPERIMENTAL
Intervention: RV1 at 6, 10, and 14 weeks
Number of subjects: 630

Group type: COMPARATOR
Intervention: RV1 at 6 and 10 weeks
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: RV1 at 10 and 14 weeks
Number of subjects: 630
Study: 22864647

Group type: EXPERIMENTAL
Intervention: CART model using variables from Norwood hospitalization
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: CART model applied to ISV trial subjects
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: PDI score lower than 70
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Risk factors for PDI lower than 70
Number of subjects: 313
Study: 20720188

Group type: EXPERIMENTAL
Intervention: tissue plasminogen activator (tPA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study: 18950439

Group type: EXPERIMENTAL
Intervention: 4% lidocaine (active) injections
Number of subjects: 15

Group type: COMPARATOR
Intervention: saline (control) injections
Number of subjects: 15
Study: 15983790

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (D-amph)
Number of subjects: 0
Study: 12598775

Group type: EXPERIMENTAL
Intervention: Nevirapine 200 mg once weekly (cohort A, n = 12)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Nevirapine 200 mg twice weekly (cohort B, n = 12)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Nevirapine 200 mg every other day (cohort C, n = 9)
Number of subjects: 33
Study: 10566923

Group type: EXPERIMENTAL
Intervention: Halothane anesthesia
Number of subjects: 12

Group type: COMPARATOR
Intervention: Balanced anesthesia
Number of subjects: 12
Study: 8604065

Group type: EXPERIMENTAL
Intervention: Lingual split technique
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional buccal approach
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 1782718

Group type: EXPERIMENTAL
Intervention: Diclofenac 50 mg preoperatively and 50 mg post-operatively
Number of subjects: 99

Group type: COMPARATOR
Intervention: Diclofenac 100 mg post-operatively only
Number of subjects: 99
Study: 6451354

Group type: EXPERIMENTAL
Intervention: Urea ointment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo ointment (urea vehicle)
Number of subjects: 0
Study: 31751935

Group type: EXPERIMENTAL
Intervention: Ketone salt (KS) supplement (0.38 g/kg body mass)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30786806

Group type: EXPERIMENTAL
Intervention: CBCT-guided TAT
Number of subjects: 88

Group type: COMPARATOR
Intervention: Conventional TAT
Number of subjects: 88
Study: 28231274

Group type: EXPERIMENTAL
Intervention: Early skin-to-skin contact (SSC)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Late skin-to-skin contact (SSC)
Number of subjects: 35
Study: 25163489

Group type: EXPERIMENTAL
Intervention: Dexamethasone 12 mg intramuscularly, two doses 24 hours apart
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care without steroids
Number of subjects: 100
Study: 24008568

Group type: EXPERIMENTAL
Intervention: 1 µg/kg remifentanil
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2 µg/kg remifentanil
Number of subjects: 30
Study: 21390920

Group type: EXPERIMENTAL
Intervention: Verbal training condition
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Spatial training condition
Number of subjects: 47
Study: 19155905

Group type: EXPERIMENTAL
Intervention: Dipslide culture technique
Number of subjects: 3048

Group type: EXPERIMENTAL
Intervention: Leukocyte esterase and nitrite dipsticks
Number of subjects: 3048
Study: 16881118

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15359017

Group type: EXPERIMENTAL
Intervention: Mortality salience
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subliminal exposure to 9/11-related stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reminders of mortality and 9/11
Number of subjects: 0
Study: 11526556

Group type: EXPERIMENTAL
Intervention: Discectomy
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Arthroscopic lysis and lavage
Number of subjects: 22
Study: 9416896

Group type: EXPERIMENTAL
Intervention: Ibutilide
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Procainamide
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study: 7581113

Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2b
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Donor mononuclear cells with or without interleukin-2
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cytokine-mediated immunotherapy
Number of subjects: 6
Study: 2198301

Group type: EXPERIMENTAL
Intervention: Buspirone 5-30 mg/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 352099

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 42

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 42
Study: 31347384

Group type: EXPERIMENTAL
Intervention: Standardized video plus usual consent process
Number of subjects: 327

Group type: COMPARATOR
Intervention: Usual consent process alone
Number of subjects: 327
Study: 28284835

Group type: EXPERIMENTAL
Intervention: My Care My Call (MCMC) intervention
Number of subjects: 84

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 84
Study: 25545376

Group type: EXPERIMENTAL
Intervention: Ferric maltol (30 mg twice a day)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 25202177

Group type: EXPERIMENTAL
Intervention: Kinesio Taping (KT) combined with conventional physical therapy (n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional physical therapy only (n=20)
Number of subjects: 40
Study: 22442069

Group type: EXPERIMENTAL
Intervention: Acute stress during encoding
Number of subjects: 44
Study: 19445652

Group type: EXPERIMENTAL
Intervention: Tapentadol IR 50 mg
Number of subjects: 901

Group type: EXPERIMENTAL
Intervention: Tapentadol IR 75 mg
Number of subjects: 901

Group type: EXPERIMENTAL
Intervention: Oxycodone HCl IR 10 mg
Number of subjects: 901

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 901
Study: 17242081

Group type: EXPERIMENTAL
Intervention: Fiberoptic Nasotracheal Intubation (FNI)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Fiberoptic Orotracheal Intubation (FOI)
Number of subjects: 66
Study: 14981334

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 13
Study: 11752036

Group type: EXPERIMENTAL
Intervention: Fish oil (4000 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control oil (4000 mg)
Number of subjects: 24
Study: 9056732

Group type: EXPERIMENTAL
Intervention: Traditional rice-lentil (khitchri) diet (KY)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Traditional rice-lentil (khitchri) diet with soy formula (KY-Soy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Traditional rice-lentil (khitchri) diet with dilute buffalo milk (KY-B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Traditional diet and yogurt combination
Number of subjects: 0
Study: 7686187

Group type: EXPERIMENTAL
Intervention: 0.025% tretinoin cream applied once daily for 9 months
Number of subjects: 6

Group type: COMPARATOR
Intervention: Vehicle cream applied once daily for 9 months
Number of subjects: 6
Study: 3523043

Group type: EXPERIMENTAL
Intervention: Adjuvant chemo-immunotherapy (BCG or BCG plus tumor cell vaccine)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy (CMF)
Number of subjects: 131
Study: 30058744

Group type: EXPERIMENTAL
Intervention: nature sounds
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: nature sounds and daylight
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: nature sounds, daylight, and colour enhancements
Number of subjects: 200

Group type: COMPARATOR
Intervention: control
Number of subjects: 200
Study: 27272818

Group type: EXPERIMENTAL
Intervention: Continuous infusion RSB analgesia
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Combined active groups (single-dose, repeated-dose, continuous infusion)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 46
Study: 25342504

Group type: EXPERIMENTAL
Intervention: Cisplatin with nolatrexed (LP)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Cisplatin with 5-fluorouracil (FP)
Number of subjects: 33
Study: 22290239

Group type: EXPERIMENTAL
Intervention: Raltegravir
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control (no raltegravir)
Number of subjects: 69
Study: 20482478

Group type: EXPERIMENTAL
Intervention: 4 weeks of serial night casting
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 4 weeks of weightbearing stretches
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 17610993

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied thrice weekly for 8 weeks
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied thrice weekly for 12 weeks
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied thrice weekly for both durations
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied thrice weekly
Number of subjects: 90
Study: 16083538

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) dry powder inhaler (DPI) 400 microg qd PM (one inhalation)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) dry powder inhaler (DPI) 400 microg qd PM (two inhalations)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) dry powder inhaler (DPI) 200 microg qd PM
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) dry powder inhaler (DPI) 200 microg bid
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 11935106

Group type: EXPERIMENTAL
Intervention: Magnetic resonance discography using gadopentetate dimeglumine
Number of subjects: 13

Group type: COMPARATOR
Intervention: Computed tomographic discography using intradiscal iodinated contrast agent
Number of subjects: 13
Study: 10444726

Group type: EXPERIMENTAL
Intervention: Attendance at organized breast cancer screening program
Number of subjects: 1680

Group type: COMPARATOR
Intervention: Expectation of pain at mammography
Number of subjects: 1680

Group type: COMPARATOR
Intervention: Low confidence in breast cancer prevention capabilities
Number of subjects: 1680

Group type: COMPARATOR
Intervention: Overoptimism about the sensitivity of mammography
Number of subjects: 1680

Group type: COMPARATOR
Intervention: Perception of breast cancer risk as moderate
Number of subjects: 1680
Study: 8544973

Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Buspirone 5 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 1921538

Group type: EXPERIMENTAL
Intervention: Cost-sharing
Number of subjects: 0
Study: 7311224

Group type: EXPERIMENTAL
Intervention: Autotransfusion (AT)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Bank blood transfusion (control)
Number of subjects: 144
Study: 31822114

Group type: EXPERIMENTAL
Intervention: Olive-pomace oil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Crude pomace-oil
Number of subjects: 0
Study: 30795852

Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg/day
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 27667534

Group type: EXPERIMENTAL
Intervention: KneeAlign (portable navigation device)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Conventional guides
Number of subjects: 190
Study: 27233633

Group type: EXPERIMENTAL
Intervention: Tailored implementation intervention
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study: 25528574

Group type: EXPERIMENTAL
Intervention: Erythropoietin 40,000 IU administered weekly for up to three doses
Number of subjects: 606

Group type: COMPARATOR
Intervention: Placebo administered weekly for up to three doses
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 606

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 606
Study: 22670572

Group type: EXPERIMENTAL
Intervention: Compassionate imagery
Number of subjects: 24

Group type: COMPARATOR
Intervention: Relaxation (Control)
Number of subjects: 24
Study: 19884557

Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Trastuzumab with docetaxel or vinorelbine
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Docetaxel, trastuzumab, and FEC
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Vinorelbine, trastuzumab, and FEC
Number of subjects: 1010

Group type: COMPARATOR
Intervention: Trastuzumab
Number of subjects: 1010
Study: 17535142

Group type: EXPERIMENTAL
Intervention: Physiotherapy intervention from Monday to Saturday
Number of subjects: 262

Group type: COMPARATOR
Intervention: Physiotherapy intervention from Monday to Friday
Number of subjects: 262
Study: 15171968

Group type: EXPERIMENTAL
Intervention: Nurse-led follow-up on demand (NG)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Physician follow-up (PG)
Number of subjects: 264
Study: 11797323

Group type: EXPERIMENTAL
Intervention: Conductive keratoplasty (CK)
Number of subjects: 233
Study: 9548624

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol (50 mg daily)
Number of subjects: 2132

Group type: EXPERIMENTAL
Intervention: Beta-carotene (20 mg daily)
Number of subjects: 2132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2132
Study: 7991935

Group type: EXPERIMENTAL
Intervention: Addition of 30 cm of dead space (VD)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Replacement of 30 cm VD with 60 cm VD
Number of subjects: 15
Study: 2511693

Group type: EXPERIMENTAL
Intervention: 0.025 mg nitroglycerin intravenously
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 4544476

Group type: EXPERIMENTAL
Intervention: Polarizing solution: continuous intravenous perfusion during 7 days of one liter daily of a 10% glucose solution with potassium (40 m Eq/L) and insulin (20 units)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control group: slow perfusion (one liter daily) of a 5% glucose solution
Number of subjects: 174

Group type: COMPARATOR
Intervention: Both groups (polarized and control)
Number of subjects: 174
Study: 31602699

Group type: EXPERIMENTAL
Intervention: Xenograft alone
Number of subjects: 14

Group type: COMPARATOR
Intervention: Composite graft (autogenous bone chips and xenograft)
Number of subjects: 14
Study: 31480755

Group type: EXPERIMENTAL
Intervention: TransGender Specific Course and Workshop (TGSC&W) with film-forum methodology (G1)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: TransGender Specific Course and Workshop (TGSC&W) with problem-based learning (PBL) methodology (G2)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group (no specific classes or workshops)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Comparison between film-forum and PBL methodologies
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Satisfaction with learning methodology
Number of subjects: 116
Study: 28700892

Group type: EXPERIMENTAL
Intervention: Healthy Eating and Active Living for Diabetes and Gestational Diabetes Mellitus (HEALD‐GDM) program, 24-week program led by an Exercise Specialist
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 100
Study: 26279580

Group type: EXPERIMENTAL
Intervention: Caffeinated energy drink (3 mg/kg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (0 mg/kg)
Number of subjects: 14
Study: 24490265

Group type: EXPERIMENTAL
Intervention: Daily multivitamin
Number of subjects: 5947

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5947
Study: 20962338

Group type: EXPERIMENTAL
Intervention: High-dose tirofiban (HDT) pretreatment
Number of subjects: 984

Group type: COMPARATOR
Intervention: Placebo pretreatment
Number of subjects: 984

Group type: EXPERIMENTAL
Intervention: Bail-out use of study medication
Number of subjects: 984

Group type: EXPERIMENTAL
Intervention: HDT bail-out
Number of subjects: 984

Group type: COMPARATOR
Intervention: Placebo bail-out in patients pretreated with HDT
Number of subjects: 984
Study: 18328334

Group type: EXPERIMENTAL
Intervention: Treatment (specific pharmacologic treatment not detailed)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Baseline (no specific intervention mentioned)
Number of subjects: 126

Group type: COMPARATOR
Intervention: On treatment (no specific intervention mentioned)
Number of subjects: 126
Study: 16416102

Group type: EXPERIMENTAL
Intervention: Physical therapy agents (PTA) applied five times a week for 3 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Hylan G-F 20 or sodium hyaluronate (NaHA) administered weekly intra-articular during the first 3 weeks and in the sixth month
Number of subjects: 80